{Reference Type}: Case Reports
{Title}: Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction: A Case Report.
{Author}: Endo Y;Kamo N;Kato A;Sato T;Okabe C;Furukawa S;Watanabe T;Soeda S;
{Journal}: In Vivo
{Volume}: 38
{Issue}: 2
{Year}: 2024 Mar-Apr
{Factor}: 2.406
{DOI}: 10.21873/invivo.13527
{Abstract}: <B>BACKGROUND: </B>Polyadenosine 5'-diphosphoribose polymerase inhibitors (PARP-Is) are novel, effective agents for treating newly diagnosed epithelial ovarian cancer (EOC). However, the effect of PARP-I on the progression of recurrent EOC has not yet been determined. In particular, there is limited evidence regarding retreatment with PARP-I for recurrent EOC that has progressed on PARP-I in the short term.<BR><B>METHODS: </B>A 69-year-old woman with a BRCA1 mutated EOC relapsed five months after starting olaparib maintenance following neoadjuvant chemotherapy and interval debulking surgery. Although the platinum-free interval was within six months, secondary cytoreductive surgery was performed because the tumor was locoregional. Following two cycles of weekly nedaplatin, niraparib induced a complete response, and the patient maintained a progression-free status for 15 months.<BR><B>CONCLUSIONS: </B>Even with short-term progression on PARP-I, local control combined with different platinum agents and PARP-I can be used to achieve good responses.